芦可替尼联合自体外周血干细胞移植治疗难治性成人斯蒂尔病一例  

Prolonged remission state of refractory adult-onset Still's disease treated with ruxolitinib combined with autologous peripheral blood stem cell transplantation:a case report

作　　者：王倩[1,2] 秦玲 WANG Qian;QIN Ling(Clinical Medical College,Henan University of Science and Technology,Henan Luoyang 471003,China;Department of Hematology,the First Affiliated Hospital of Henan University of Science and Technology,Henan Luoyang 471003,China)

机构地区：[1]河南科技大学临床医学院,河南洛阳471003 [2]河南科技大学第一附属医院血液内科,河南洛阳471003

出　　处：《临床药物治疗杂志》2024年第4期90-92,共3页Clinical Medication Journal

基　　金：河南省教育厅高校重点科研项目(22A320017)。

摘　　要：本文报道了1例病史长达10年的难治性成人斯蒂尔病患者,疾病复发就诊,常规治疗无效,病情危重。给予芦可替尼联合激素口服控制炎症因子风暴,行自体外周血干细胞移植重建免疫,并在移植后口服小剂量芦可替尼维持治疗,实现近34个月的缓解。因此,通过对该患者的诊疗过程,结合相关文献,论证了造血干细胞移植序贯芦可替尼治疗难治性成人斯蒂尔病的可行性,为难治性患者提供了一种新的治疗思路。A patient with a 10-year history of adult-onset Still's disease relapsed.He developed into a critical condition after failing to respond to conventional therapy.The patient was treated with ruxolitinib plus oral steroids to control the inflam⁃matory storm,autologous peripheral blood stem cell transplantation was performed for immune reconstitution,and mainte⁃nance therapy was conducted with oral low-dose ruxolitinib after transplantation.He achieved remission for nearly 34 months.This case demonstrated the feasibility of hematopoietic stem cell transplantation followed by ruxolitinib for refractory adult Still's disease,which provided a new treatment idea for refractory patients.

关 键 词：成人斯蒂尔病 芦可替尼 自体外周血干细胞移植 

分 类 号：R969.3[医药卫生—药理学]